- Home
- TSAT vs LXEO Comparison
TSAT vs LXEO Comparison
Compare TSAT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- LXEO
- Stock Information
- Founded
- TSAT 1969
- LXEO 2017
- Country
- TSAT Canada
- LXEO United States
- Employees
- TSAT N/A
- LXEO N/A
- Industry
- TSAT Metal Fabrications
- LXEO
- Sector
- TSAT Industrials
- LXEO
- Exchange
- TSAT Nasdaq
- LXEO Nasdaq
- Market Cap
- TSAT 394.3M
- LXEO 290.5M
- IPO Year
- TSAT 1996
- LXEO 2023
- Fundamental
- Price
- TSAT $24.31
- LXEO $5.46
- Analyst Decision
- TSAT
- LXEO Strong Buy
- Analyst Count
- TSAT 0
- LXEO 7
- Target Price
- TSAT N/A
- LXEO $15.29
- AVG Volume (30 Days)
- TSAT 87.7K
- LXEO 430.0K
- Earning Date
- TSAT 11-13-2025
- LXEO 11-12-2025
- Dividend Yield
- TSAT N/A
- LXEO N/A
- EPS Growth
- TSAT N/A
- LXEO N/A
- EPS
- TSAT N/A
- LXEO N/A
- Revenue
- TSAT $358,754,564.00
- LXEO N/A
- Revenue This Year
- TSAT N/A
- LXEO N/A
- Revenue Next Year
- TSAT N/A
- LXEO N/A
- P/E Ratio
- TSAT N/A
- LXEO N/A
- Revenue Growth
- TSAT N/A
- LXEO N/A
- 52 Week Low
- TSAT $10.11
- LXEO $1.45
- 52 Week High
- TSAT $29.91
- LXEO $11.72
- Technical
- Relative Strength Index (RSI)
- TSAT 56.03
- LXEO 66.98
- Support Level
- TSAT $20.81
- LXEO $5.15
- Resistance Level
- TSAT $27.83
- LXEO $5.56
- Average True Range (ATR)
- TSAT 1.51
- LXEO 0.30
- MACD
- TSAT 0.56
- LXEO 0.02
- Stochastic Oscillator
- TSAT 56.00
- LXEO 89.13
About TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.